Novo Next-Generation Obesity Shot Falls Short of Lilly Rival
Why it matters
Novo Nordisk's next-generation obesity shot, CagriSema, failed to deliver the expected weight loss compared to Eli Lilly's rival tirzepatide, dealing another blow to Novo's efforts in the weight-loss market.
Article tone
Expected market reaction
Market impact analysis based on bearish sentiment with 85% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 49035
Original source
Novo Nordisk’s next-generation obesity shot delivered less weight loss than Eli Lilly rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Sam Fazeli of Bloomberg Intelligence joins to discuss. He also breaks down how Merck is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer drug Keytruda. (Source: Bloomberg)
Read the full article on Bloomberg
Original article published by Bloomberg on February 23, 2026. Analysis and insights provided by AnalystMarkets AI.